Catherine J. Kennedy

ORCID: 0000-0002-4465-5784 · 4 papers in corpus · active 2018-2022

Study types

  • other 2
  • article 1
  • preprint 1

Condition tags

  • endometriosis 4
other 2022
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.CCR-21-3817

PURPOSE: To identify molecular subclasses of clear cell ovarian carcinoma (CCOC) and assess their impact on clinical presentation and outcomes. EXPERIMENTAL DESIGN: We profiled 421 primary CCOCs that passed quality control using a targeted…

preprint 2021
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

article 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 + TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
The Journal of Pathology ·doi:10.1002/path.5849

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory rep…

other 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
The journal of pathology. Clinical research ·doi:10.1002/cjp2.109

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemi…